To date, studies on the potential effect of drugs with proven cardio-renal benefits in diabetes, such as glucagon-like peptide 1 agonists (GLP1-as) and sodium-glucose co-transporter-2 inhibitors (SGLT2is), on p300 regulation are lacking. The gene discussed is GCG; the disease is diabetes mellitus.